<p>DBV Technologies S.A.（纳斯达克代码：DBVT - 获取免费报告）在周四交易前出现了跳空上涨。该股票此前收于 20.00 美元，但开盘价为 20.85 美元。DBV Technologies 的股票最后交易价格为 19.5350 美元，成交量为 161,540 股。</p>
<p>获取 <strong>DBV Technologies</strong> 的提醒：</p>
<h2>分析师设定新的价格目标</h2>
<ul>
<li>3 只生物制药股票逆势而上</li>
</ul>
<p>几位股票分析师最近对 DBVT 股票发布了报告。HC Wainwright 在 10 月 29 日的研究报告中重申了 “买入” 评级，并将 DBV Technologies 的目标价格从 16.00 美元上调至 20.00 美元。Weiss Ratings 在周一的报告中重申了对 DBV Technologies 的 “卖出（d-）” 评级。Zacks Research 在 9 月 29 日的研究报告中将 DBV Technologies 的评级从 “强烈卖出” 上调至 “持有”。Wall Street Zen 在 11 月 28 日的报告中将 DBV Technologies 的评级从 “卖出” 上调至 “持有”。最后，Guggenheim 在 12 月 3 日的报告中开始覆盖 DBV Technologies。他们对该股票给予了 “买入” 评级，并设定了 35.00 美元的目标价格。一位投资分析师给予该股票 “强烈买入” 评级，四位给予 “买入” 评级，一位给予 “持有” 评级，两位给予 “卖出” 评级。根据 MarketBeat.com 的数据，该公司的平均评级为 “适度买入”，共识目标价格为 20.81 美元。</p>
<p><strong>获取我们最新的 DBVT 股票分析</strong></p>
<h2>DBV Technologies 股票下跌 3.2%</h2>
<p>该公司的市值为 7.531 亿美元，市盈率为-3.75，贝塔值为-1.10。该股票的 50 日移动平均线为 14.55 美元，200 日移动平均线为 11.29 美元。</p>
<h2>DBV Technologies 的机构交易</h2>
<p>对冲基金和其他机构投资者最近对该公司的持仓进行了调整。Vivo Capital LLC 在第二季度购买了 DBV Technologies 的新股份，价值约为 9,659,000 美元。Adage Capital Partners GP L.L.C.在第二季度购买了 DBV Technologies 的新股份，价值 9,659,000 美元。MPM Bioimpact LLC 在第二季度购买了 DBV Technologies 的新股份，价值约为 9,649,000 美元。Octagon Capital Advisors LP 在第二季度购买了 DBV Technologies 的新股份，价值约为 9,315,000 美元。最后，Millennium Management LLC 在第三季度将其在 DBV Technologies 的股份增加了 26.1%。Millennium Management LLC 目前拥有 337,863 股该公司的股票，价值 3,379,000 美元，此前在上个季度又购买了 69,849 股。71.74% 的股票目前由机构投资者持有。</p>
<h2>DBV Technologies 公司简介</h2>
<p>（获取免费报告）</p>
<p>DBV Technologies SA 是一家临床阶段的生物制药公司，专注于皮肤免疫治疗产品的研究和开发。其产品管线包括 Viaskin Peanut，这是一种免疫治疗产品，已完成针对花生过敏的第三阶段临床试验；以及 Viaskin Milk，目前正在进行针对免疫球蛋白 E（IgE）介导的牛奶蛋白过敏和嗜酸性食管炎的第一/二阶段临床试验。</p>
<h2>推荐故事</h2>
<ul>
<li>五只我们更看好的股票，胜过 DBV Technologies</li>
<li>3 只防御类股票将受益于军事支出增加</li>
<li>顶级 3 只冬季股票，具有良好的增长机会</li>
<li>10 月值得考虑购买的 3 只股票</li>
<li>2026 年反弹选择：3 只标普滞后股有望突破</li>
<li>什么是股息之王？</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 DBV Technologies 吗？</h2>
<p>在你考虑 DBV Technologies 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 DBV Technologies 并不在名单上。</p>
<p>虽然 DBV Technologies 目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

DBV 科技

<p>DBV 科技（NASDAQ:DBVT）在周四交易前股价跳涨，开盘价为 $20.85，较前一交易日收盘价 $20.00 上涨。该股票最后交易价格为 $19.5350。分析师的评级意见不一：HC Wainwright 将评级上调至 “买入”，目标价为 $20.00，Weiss Ratings 评级为 “卖出（d-）”，Zacks Research 将评级上调至 “持有”，Wall Street Zen 也将评级上调至 “持有”，而 Guggenheim 则首次覆盖，给予 “买入” 评级和 $35.00 的目标价。机构投资者最近增加了在 DBV 科技的持仓</p>

<p>DBV Technologies S.A. (NASDAQ:DBVT - Get Free Report) gapped up prior to trading on Thursday . The stock had previously closed at $20.00, but opened at $20.85. DBV Technologies shares last traded at $19.5350, with a volume of 161,540 shares changing hands.</p>
<div class="lb-trans"><p>DBV Technologies S.A.（纳斯达克代码：DBVT - 获取免费报告）在周四交易前出现了跳空上涨。该股票此前收于 20.00 美元，但开盘价为 20.85 美元。DBV Technologies 的股票最后交易价格为 19.5350 美元，成交量为 161,540 股。</p>
</div><p>Get <strong>DBV Technologies</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>DBV Technologies</strong> 的提醒：</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新的价格目标</h2>
</div><ul>
<li>3 Biopharmaceutical Stocks Bucking the Sell-Off</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只生物制药股票逆势而上</li>
</ul>
</div><p>Several equities analysts recently issued reports on DBVT shares. HC Wainwright restated a &#34;buy&#34; rating and set a $20.00 price objective (up from $16.00) on shares of DBV Technologies in a research note on Wednesday, October 29th. Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of DBV Technologies in a report on Monday. Zacks Research raised shares of DBV Technologies from a &#34;strong sell&#34; rating to a &#34;hold&#34; rating in a research report on Monday, September 29th. Wall Street Zen raised shares of DBV Technologies from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a report on Friday, November 28th. Finally, Guggenheim started coverage on DBV Technologies in a report on Wednesday, December 3rd. They issued a &#34;buy&#34; rating and a $35.00 price target on the stock. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $20.81.</p>
<div class="lb-trans"><p>几位股票分析师最近对 DBVT 股票发布了报告。HC Wainwright 在 10 月 29 日的研究报告中重申了 “买入” 评级，并将 DBV Technologies 的目标价格从 16.00 美元上调至 20.00 美元。Weiss Ratings 在周一的报告中重申了对 DBV Technologies 的 “卖出（d-）” 评级。Zacks Research 在 9 月 29 日的研究报告中将 DBV Technologies 的评级从 “强烈卖出” 上调至 “持有”。Wall Street Zen 在 11 月 28 日的报告中将 DBV Technologies 的评级从 “卖出” 上调至 “持有”。最后，Guggenheim 在 12 月 3 日的报告中开始覆盖 DBV Technologies。他们对该股票给予了 “买入” 评级，并设定了 35.00 美元的目标价格。一位投资分析师给予该股票 “强烈买入” 评级，四位给予 “买入” 评级，一位给予 “持有” 评级，两位给予 “卖出” 评级。根据 MarketBeat.com 的数据，该公司的平均评级为 “适度买入”，共识目标价格为 20.81 美元。</p>
</div><p><strong>Get Our Latest Stock Analysis on DBVT</strong></p>
<div class="lb-trans"><p><strong>获取我们最新的 DBVT 股票分析</strong></p>
</div><h2>DBV Technologies Stock Down 3.2%</h2>
<div class="lb-trans"><h2>DBV Technologies 股票下跌 3.2%</h2>
</div><p>The firm has a market cap of $753.10 million, a price-to-earnings ratio of -3.75 and a beta of -1.10. The stock's 50 day moving average is $14.55 and its 200 day moving average is $11.29.</p>
<div class="lb-trans"><p>该公司的市值为 7.531 亿美元，市盈率为-3.75，贝塔值为-1.10。该股票的 50 日移动平均线为 14.55 美元，200 日移动平均线为 11.29 美元。</p>
</div><h2>Institutional Trading of DBV Technologies</h2>
<div class="lb-trans"><h2>DBV Technologies 的机构交易</h2>
</div><p>Hedge funds and other institutional investors have recently made changes to their positions in the business. Vivo Capital LLC bought a new stake in DBV Technologies during the second quarter worth approximately $9,659,000. Adage Capital Partners GP L.L.C. bought a new stake in shares of DBV Technologies during the 2nd quarter worth $9,659,000. MPM Bioimpact LLC purchased a new position in DBV Technologies in the 2nd quarter worth about $9,649,000. Octagon Capital Advisors LP purchased a new position in DBV Technologies in the 2nd quarter worth about $9,315,000. Finally, Millennium Management LLC lifted its stake in DBV Technologies by 26.1% during the third quarter. Millennium Management LLC now owns 337,863 shares of the company's stock valued at $3,379,000 after buying an additional 69,849 shares in the last quarter. 71.74% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>对冲基金和其他机构投资者最近对该公司的持仓进行了调整。Vivo Capital LLC 在第二季度购买了 DBV Technologies 的新股份，价值约为 9,659,000 美元。Adage Capital Partners GP L.L.C.在第二季度购买了 DBV Technologies 的新股份，价值 9,659,000 美元。MPM Bioimpact LLC 在第二季度购买了 DBV Technologies 的新股份，价值约为 9,649,000 美元。Octagon Capital Advisors LP 在第二季度购买了 DBV Technologies 的新股份，价值约为 9,315,000 美元。最后，Millennium Management LLC 在第三季度将其在 DBV Technologies 的股份增加了 26.1%。Millennium Management LLC 目前拥有 337,863 股该公司的股票，价值 3,379,000 美元，此前在上个季度又购买了 69,849 股。71.74% 的股票目前由机构投资者持有。</p>
</div><h2>DBV Technologies Company Profile</h2>
<div class="lb-trans"><h2>DBV Technologies 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.</p>
<div class="lb-trans"><p>DBV Technologies SA 是一家临床阶段的生物制药公司，专注于皮肤免疫治疗产品的研究和开发。其产品管线包括 Viaskin Peanut，这是一种免疫治疗产品，已完成针对花生过敏的第三阶段临床试验；以及 Viaskin Milk，目前正在进行针对免疫球蛋白 E（IgE）介导的牛奶蛋白过敏和嗜酸性食管炎的第一/二阶段临床试验。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than DBV Technologies</li>
<li>3 Defense Stocks Set to Benefit From Increased Military Spending</li>
<li>Top 3 Winter Stocks With Solid Growth Opportunities</li>
<li>3 Stocks to Consider Buying in October</li>
<li>2026 Comeback Picks: 3 S&amp;P Laggards Poised to Break Out</li>
<li>What is a Dividend King?</li>
<li>Tesla Bulls See $500 Ahead—But Bears Warn of a Painful Reversal</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 DBV Technologies</li>
<li>3 只防御类股票将受益于军事支出增加</li>
<li>顶级 3 只冬季股票，具有良好的增长机会</li>
<li>10 月值得考虑购买的 3 只股票</li>
<li>2026 年反弹选择：3 只标普滞后股有望突破</li>
<li>什么是股息之王？</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in DBV Technologies Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 DBV Technologies 吗？</h2>
</div><p>Before you consider DBV Technologies, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 DBV Technologies 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DBV Technologies wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 DBV Technologies 并不在名单上。</p>
</div><p>While DBV Technologies currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 DBV Technologies 目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

DBV Technologies (NASDAQ:DBVT) 股价跳空上涨 - 是否值得购买？